

# CAMO FELLOWSHIP



**SPONSORSHIP PROSPECTUS**

# SPONSORSHIP PROSPECTUS

CAMO would like to invite you to participate as a major Fellowship sponsor and would welcome and appreciate your support. The purpose of the Fellowship Program is to build, in collaboration with industry, Canadian capacity and expertise in the area of oncology and to promote excellence in research through training awards. The goals of the program are to provide an opportunity for individuals who have completed their Medical Oncology training in Canada to have additional clinical and/or fundamental research experience. The maximum amount awarded for a single Fellowship is \$80,000 per annum for one (1) year. The award consists of an annual stipend of up to \$75,000 and an annual research allowance of \$5,000.


We appreciate that you may not be in a position to fund a full Fellowship but appreciate any support you are able to provide. We have created tiered sponsorship packages to best fit the goals of your organization.

The review committee is comprised of 5 reviewers (supported by the chair) who will demonstrate experience and excellence in research in the domains identified as priorities by the CAMO membership.

Announcement of Awards will be done the second week of December via email followed by a formal presentation to the CAMO membership during the CAMO Annual Scientific Meeting in April of 2023. It will also be acknowledged in CAMO newsletter and on the CAMO website.

Your contribution will have an important impact on the success of the Fellowship Program and we hope that we can count on your support for the 2023 Fellowship Program. On behalf of the Canadian Association of Oncologists, I look forward to hearing from you.

Yours sincerely,



David Dawe, MD, FRCPC  
Chair, CAMO Fellowship Committee

## SPONSORSHIP OPPORTUNITIES

CAMO recognizes the need for close collaboration between the organization and the corporate sector. This prospectus has been developed to identify initiatives currently being undertaken by CAMO.

### LEVELS OF COMMITMENT



**DIAMOND**  
\$80,000



**GOLD**  
\$45,000



**SILVER**  
\$10,000



**BRONZE**  
\$5,000

Compliment your company's marketing plan by increasing your visibility as an official CAMO Fellowship sponsor. Our Partnership Program offers your company opportunities to promote excellence in research through training awards.



## DIAMOND \$80,000

The Diamond Level Sponsor is the highest level of partnership and visibility offered with the CAMO. As A Diamond Level Sponsor, you will be acknowledged for your outstanding commitment to the success of the Fellowship program and will receive the highest degree of recognition.

- Presentation of a plaque acknowledging Diamond Level Sponsor at the CAMO Annual Scientific Meeting.
- Recognition as being a Diamond Level Sponsor on the home page of the CAMO website & under Fellowship section.
- Recognition of sponsorship in all promotional material related to the 2023 Fellowship.
- Acknowledgement as a Diamond Level Sponsor in the CAMO newsletter.
- Verbal recognition as a Diamond Level Sponsor during the Annual Scientific Meeting.
- Link of corporate website on the CAMO website under Fellowship section.



## GOLD \$45,000

- Recognition as being a Gold Level Sponsor on the home page of the CAMO website & under Fellowship section.
- Recognition of sponsorship in all promotional material related to the 2023 Fellowship.
- Acknowledgement as a Gold Level Sponsor in the CAMO newsletter.
- Verbal recognition as a Gold Level Sponsor during the Annual Scientific Meeting.
- Link of corporate website on the CAMO website under Fellowship section.



## SILVER \$10,000

- Recognition as being a Silver Level Sponsor on the home page of the CAMO website & under Fellowship section.
- Recognition of sponsorship in all promotional material related to the 2023 Fellowship.
- Acknowledgement as a Silver Level Sponsor in the CAMO newsletter.
- Verbal recognition as a Silver Level Sponsor during the Annual Scientific Meeting.
- Link of corporate website on the CAMO website under Fellowship section.



## BRONZE \$5,000

- Recognition as being a Bronze Level Sponsor on the home page of the CAMO website & under Fellowship section.
- Recognition of sponsorship in all promotional material related to the 2023 Fellowship
- Acknowledgement as a Bronze Level Sponsor in the CAMO newsletter
- Verbal recognition as a Bronze Level Sponsor during the Annual Scientific Meeting
- Link of corporate website on the CAMO website under Fellowship section.



# WHERE ARE THEY NOW *(past CAMO fellows)*



## Dr. Christine Simmons

5. Trinkaus M, Chin S, Wolfman W, **Simmons CE**, Clemons M. "Should urogenital atrophy in breast cancer survivors be treated with topical estrogens"? *Oncologist* 2008 Mar;13(3):222-31. Review. PubMed PMID 18378532.
6. Petrut B, **Simmons CE**, Broom R, Trinkaus M, Clemons M. "Pharmacotherapy of bone metastases in breast cancer patients". *Expert Opin Pharmacother*. 2008 Apr;9(6):937-45. Review. PubMed PMID: 18377337.
7. **Simmons CE**, Broom RJ, Cole DE, Dranitsaris G, Clemons M. "Urinary N-telopeptide is a Rapid Predictor of Response and Palliative Benefit from Bisphosphonate Therapy in Metastatic Breast Cancer Patients". *Supportive Cancer Therapy*, 2008 Sep 1;4(4):182-7. PubMed PMID: 18632515.
8. Amir E, Ooi W, **Simmons CE**, Khan H, Christaskis M, Popovic S, Kalina M, Chesney A, Singh G, Clemons M. "Discordance between receptor status in primary and metastatic breast cancer: An exploratory study of bone and bone marrow biopsies.". *Clinical Oncology, (R Coll Radio)*. 2008, Dec; 20 (10): 763-8. Epub 2008 Sept 27. PubMed PMID 18824337.
9. Chin S, Trinkaus M, **Simmons CE**, Bolivar R, Flynn C, Clemons M. "Prevalence and severity of urogenital symptoms in postmenopausal women receiving endocrine therapy for breast cancer". *Clinical Breast Cancer* 2009 May; 9(2): 108-17. PubMed PMID: 19433392.
10. Broom RJ, Tang PA, **Simmons CE**, Bordeleau L, Mulligan AM, O'Malley FP, Miller N, Andrulis IL, Brenner DM, Clemons MJ. "Changes in estrogen receptor, progesterone receptor, and Her2/neu status with time: discordance rates between primary and metastatic breast cancer.". *Anticancer Res*. 2009 May; 29(5):1557-62. PubMed PMID: 19443366.
11. Amir E, Trinkaus M, **Simmons CE**, Dranitsaris G, Clemons MJ. "Vascular endothelial growth factor activity after switching of bisphosphonate treatment for metastatic breast cancer.". *Journal of Clinical Pathology*. 2009 May; 62(5):474-6. PubMed PMID: 19398598.
12. **Simmons CE**, Amir E, Dranitsaris G, Clemons M, Wong B, Veith R, Cole DE. "Altered calcium metabolism in patient on long-term bisphosphonate therapy for metastatic breast cancer". *Anticancer Research* 2009 Jul;29(7):2707-11. PubMed PMID: 19596950.
13. Broom R, Du H, Clemons M, Eton D, Dranitsaris G, **Simmons CE**, Ooi W, Cella D. "Switching breast cancer patients with progressive bone metastases to third-generation bisphosphonates: measuring impact using the Functional Assessment of cancer Therapy-Bone Pain". *J Pain Symptom Manage*, 2009 Aug;38(2):244-57.
14. **Simmons CE**, Miller N, Geddie W, Gianfelice D, Oldfield M, Dranitsaris G, Clemons MJ. "Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?". *Ann Oncol*. 2009 Sep;20(9):1499-504. Epub 2009 Mar 18. PubMed PMID: 19299408; PubMed Central PMCID: PMC2731014.
15. Amir E, **Simmons CE**, (co-primary author), Freedman OC, Dranitsaris G, Cole DE, Vieth R, Ooi WS, Clemons M. "A phase II trial exploring the effects of high-dose (10,000IU/day) vitamin D(3) in breast cancer patients with bone metastases. *Cancer* 2010 15;116(2):284-91. PubMed PMID: 19918922.
16. Trinkaus M, **Simmons CE**, Myers J, Dranitsaris G, Clemons M. "Skeletal-related events (SREs) in breast cancer patients with bone metastases treated in the non-trial setting". *Support Care Cancer*: 2010 Feb;18(2):197-203. Epub 2009 May 8. PubMed PMID: 19424729.



# WHERE ARE THEY NOW *(past CAMO fellows)*



## Dr. Vincent Tam

### 5. Publications from CAMO Fellowship

- 1) Tam VC, Ko YJ, Mittmann N, Cheung MC, Kumar K, Hassan S, Chan KK. Cost-effectiveness of systemic therapies for metastatic pancreatic cancer. *Curr Oncol.* 2013 Apr;20(2):e90-e106.
- 2) Tam VC, Berry S, Hsu T, North S, Neville A, Chan K, Verma S. Oncology education in Canadian undergraduate and postgraduate medical programs: a survey of educators and learners. *Curr Oncol.* 2014 Feb;21(1):e75-88.
- 3) Lien K, Tam VC, Ko YJ, Mittmann N, Cheung MC, Chan KK. Impact of country-specific EQ-5D-3L tariffs on the economic value of systemic therapies used in the treatment of metastatic pancreatic cancer. *Curr Oncol.* 2015 Dec;22(6):e443-52.

## Dr. Philippe Bedard

### 1. What was your CAMO Fellowship project?

Determinants of genomic risk in early-stage breast cancer

### 2. Where did you do (location) your CAMO Fellowship?

Institut Jules Bordet, Breast International Group, Brussels, Belgium

### 3. How do you think the CAMO Fellowship influenced your career?

Through my CAMO fellowship, I gained experience in oncology clinical research, developed a network of worldwide contacts in breast cancer medicine, and catalyzed an interest in early stage drug development and clinical genomics that has shaped my early career development.

### 4. Where are you now?

Staff Medical Oncologist, Princess Margaret Cancer Centre, Associate Professor of Medicine, University of Toronto

### 5. Publications from CAMO Fellowship

1. Azim HA Jr, Michiels S, Bedard PL, Singhal SK, Criscitiello C, Ignatiadis M, Haibe-Kains B, Piccart MJ, Sotiriou C, Loi S. Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling. *Clinical Cancer Research.* 2012 Mar 1;18(5):1341-51. Impact Factor 7.742. Coauthor or Collaborator.
2. Bedard PL, Singhal SK, Ignatiadis M, Bradbury I, Haibe-Kains B, Desmedt C, Loi S, Evans DB, Michiels S, Dixon JM, Miller WR, Piccart MJ, Sotiriou C. Low residual proliferation after short-term letrozole therapy is an early predictive marker of response in high proliferative ER-positive breast cancer. *Endocrine Related Cancer.* 2011 Dec 1;18(6):721-30. Impact Factor 4.364. Principal Author.
3. Bedard PL, Cardoso F. Can some patients avoid adjuvant chemotherapy for early-stage breast cancer? *Nature Reviews Clinical Oncology.* 2011 May 1;8(5):272-9. Review. Impact Factor 11.963. Principal Author.
4. Bedard PL, Bernard-Marty C, Raimondi C and Cardoso F. The role of capecitabine in the management of breast cancer in elderly patients. *Journal of Geriatric Oncology.* 2011;2(1):72-81. Impact Factor 1.18. Principal Author.
5. Toussaint J, Durbecq V, Altintas S, Doriath v, Rouas G, Paesmans M, Bedard B, Haibe-Kains B, Tjalma WA, Larsimont D, Piccart M, Sotiriou C. Low CD10 mRNA Expression Identifies High-Risk Ductal Carcinoma In Situ (DCIS). *PLoS ONE.* 5:pii:e12100, August 2010. Impact Factor 4.411. Coauthor or Collaborator.
6. Knauer M, Cardoso F, Wesseling J, Bedard PL, Linn SC, Rutgers EJ, van 't Veer LJ. Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature. *British Journal of Cancer.* 2010;103(12):1788-93. 2010 Nov 16. [Epub ahead of print]. Impact Factor 5.042. Coauthor or Collaborator.
7. Bedard PL, Di Leo A, Piccart-Gebhart MJ. Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer. *Nature Reviews Clinical Oncology.* 2010;7(1):22-36. Review. Impact Factor 11.963. Principal Author.

# WHERE ARE THEY NOW *(past CAMO fellows)*



Dr. Philippe Bedard

8. Tomasello G, Bedard PL, de Azambuja E, Llossignol D, Devriendt D, Piccart-Gebhart MJ. Brain metastases in HER2-positive breast cancer: the evolving role of lapatinib. *Critical Reviews Oncology & Hematology*. 2010;75(2):110-21. [Epub ahead of print]. Impact Factor 4.411. Coauthor or Collaborator.
9. Bedard PL, Piccart-Gebhart MJ. Progress in tailoring adjuvant endocrine therapy for postmenopausal women with early breast cancer. *Curr Opin Oncol*. 2009 Nov 1;21(6):491-8. Review. Impact Factor 4.1. Principal Author.
10. Bedard PL, Body J-J, and Piccart-Gebhart MJ. Sowing the Soil for Cure? The Evolving Adjuvant Bisphosphonate Story in Early Breast Cancer. *J Clin Oncol*. 2009 Aug 3;27:4043-4046. Editorial. Impact Factor 18.372. Principal Author.
12. Bedard PL, Mook S, Piccart-Gebhart MJ, Rutgers ET, Van't Veer LJ, Cardoso F. MammaPrint 70-gene profile quantifies the likelihood of recurrence for early breast cancer. *Expert Opin Med Diagn*. 2009 Mar 1;3(2):193-205. Principal Author.
13. Snoj N, Bedard PL, de Azambuja E, Cardoso F, and Piccart M. Are we HER-ting for innovation in neoadjuvant clinical trial design? *Br Cancer Res*. 2009 Jan 16;11(1):201. Impact Factor 5.245. Coauthor or Collaborator.
14. Cardoso F, Bedard PL, Winer EP, Pagani O, Senkus-Konefka E, Fallowfield LJ, Kyriakides S, Costa A, Cufer T, Albain KS, ESO-MBC Task Force. International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. *J Natl Cancer Inst*. 2009;101(17):1174-81. [Epub ahead of print] August 5, 2009. Impact Factor 13.757. Co-Principal Author.
15. de Azambuja E, Bedard PL, Suter T, Piccart-Gebhart M. Cardiac toxicity with anti-HER-2 therapies: what have we learned so far? *Target Oncol*. 2009;4(2):77-88. Review. Impact Factor 2.76. Coauthor or Collaborator.
16. Bedard PL, Cardoso F, Piccart-Gebhart MJ. Stemming resistance to HER-2 targeted therapy. *J Mammary Gland Biol Neoplasia*. 2009;14(1):55-66. Review. Impact Factor 7.524. Principal Author.
17. Bedard PL, Dinh P, Sotiriou C, and Piccart-Gebhart MJ. Aiming at the target: improved adjuvant medical therapy. *Breast*. 2009;Suppl 3:S25-30. Impact Factor 1.97. Principal Author.
18. Snoj N, Bedard PL, de Azambuja E, Cardoso F, Piccart M. Are we HER-ting for innovation in neoadjuvant breast cancer trial design? *Breast Cancer Res*. 2009;11(1):201. Coauthor or Collaborator.
19. Bedard PL, de Azambuja E, Cardoso F. Beyond trastuzumab: overcoming resistance to targeted HER-2 therapy in breast cancer. *Curr Cancer Drug Targets*. 2009;9(2):148-62. Review. Impact Factor 4.33. Principal Author.
20. Bedard PL, Cardoso F. Recent advances in adjuvant systemic therapy for early-stage breast cancer. *Ann Oncol*. 2008 Jul 1;19 Suppl 5:v122-7. Review. Impact Factor 6.425. Principal Author.
21. Bedard PL, Piccart-Gebhart MJ. Nonhormonal systemic therapy for advanced breast cancer: do the math! *J Natl Cancer Inst*. 2008;100(24):1745-7. Editorial. Impact Factor 13.757. Principal Author.
22. Bedard PL, Piccart-Gebhart MJ. Current paradigms for the use of HER2-targeted therapy in early-stage breast cancer. *Clin Breast Cancer*. 2008;8 Suppl 4:S157-65. Review. Impact Factor 2.339. Principal Author.